Abstract
Primary plasma cell leukemia (PPCL) is an uncommon and very aggressive hematological disease, which has different cytogenetic abnormalities, special molecular and biological characteristics, compared with multiple myeloma(MM). The clinical course is unfavorable with short remissions and reduced overall survival(OS). Intensive chemotherapy regimens and bortezomib-based regimens, immunoregulatory drugs(IMiDs) as well as stem cell transplantation may be beneficial to PPCL patients. This review summarizes the recent advances of this malignant disease, including clinical and biochemical characteristics of PPCL, therapy and prognosis of PPCL, new drugs for PPCL and so on.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
